08 Aug NexPlasmaGen’s New Board Director and New Advisor
Montreal / August 8, 2024 – NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen!
David Uffer, M.A, MBA joins NexPlasmaGen’s Board of Directors. David is a 30+ yr seasoned executive having a career dedicated to the Medtech industry. He currently serves as the Managing Director of MedTech at Trinity Life Sciences, a 1200-person global management and strategy consulting firm. Before, David was the VP, Medtech of General Inception where he led company formation and venture investments and the portfolio in early-stage companies. David was also previously the Senior Partner and VP of Medtech at a global consulting and investment banking firm. 25 years before, David led BD for a $5B division of Medtronic (legacy Covidien) in their respiratory, monitoring and med/surg products. He ran deals in M&A, distribution, co-development and executed minority equity investments in companies of strategic interest. Prior to Medtronic, David was Director of Corporate Development at Hologic developing company strategy and executing deals across gyn surgery, breast health, and molecular diagnostics. David also has managed Boston Scientific’s strategy and business development function in vascular surgery, interventional medicine and oncology. He has held management roles at Integra Lifesciences directing neuromonitoring and neurosurgery business units. David initiated his career with Abbott Labs in their global business intelligence function.
NexPlasmaGen welcomes Edward J. Dougherty, ThM, MDiv, MS, BA, as a member of NexPlasmaGen’s Business Development Advisory Board. Edward, with over 30-yr experience, is Principal at dougherty.consulting llc, a boutique regulatory and reimbursement consultancy in Washington, DC with a focus on U.S. market access for Medtech companies. Prior to his current position, Edward was Principal at Dentons US, the world’s largest global law firm, assisting MedTech compagnies pre- and post-market, global market access and federal advocacy. Before, Edward was a Senior Health Policy Advisor at Arent Fox (now Arent Fox Schiff), a go-to advisors’ firm, where he develops strategies to access the US and global market for Medtech companies. Previously, he was also Senior VP at B&D Consulting (now FaegreDrinker), where he assisted Medtech companies in regulatory risk/benefit analysis and compliance. Prior to that, he was Senior VP at McKesson Corporation – Pharmaceutical Partners Group, where he launched the postmarket Patient Registries Department and VP at Parexel International, where he led the strategic consulting practice, comprising postmarket study design and management, health outcomes research, payment policy, and health communications teams.
NexPlasmaGen is privileged to benefit from David and Edward’s expertise to accelerate the commercialization of its medical technology strategically and thoughtfully.
ABOUT NEXPLASMAGEN
NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.
Contact
Valérie Léveillé, CEO/Founder
1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/
No Comments